Pulse Biosciences, Inc. PLSE

HAYWARD, Calif., September 15, 2026--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced two milestones in the PRECISE-BTN clinical study evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for the treatment of symptomatic benign thyroid nodules (BTNs). The first patient enrolled in the study completed the final 12-month follow-up visit in August at Sara

HAYWARD, Calif., August 18, 2026--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that the Compensation Committee of its Board of Directors has granted equity awards to five new employees as equity inducement awards outside of the Company's 2017 Equity Incentive Plan, but under the terms of the 2017 Inducement Equity Incentive Plan. The equity awards were approved and issued

Pulse Biosciences has delivered a very strong share price run, with recent enthusiasm around its atrial fibrillation program now sitting against valuation checks that point to a stock that screens expensive rather than cheap. Over the past 3 years, Pulse Biosciences has returned about 431.5%, which puts a lot of expectation into the current price. Progress in the NANOPULSE-AF pivotal clinical study and advancing regulatory work can support hopes for future commercialisation, while any delay...

Pulse Biosciences (PLSE) is back in focus after reporting wider second quarter losses and announcing a $75 million at the market follow on equity offering, a combination that directly affects existing shareholders. See our latest analysis for Pulse Biosciences. The recent earnings release and the $75 million at the market offering have come after a strong run in Pulse Biosciences' share price, with a 30 day share price return of 55.30% and a 90 day share price return of 73.92%. Over a longer...

Moby summary of Pulse Biosciences, Inc.'s Q2 2026 earnings call

Pulse Biosciences Inc (PLSE) surpasses halfway mark in pivotal NanoPulse-AF study, reporting 100% freedom from AF at six months and raising $57.5 million to extend cash runway through key milestones.

HAYWARD, Calif., August 06, 2026--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced business updates and financial results for the second quarter ended June 30, 2026.